4-溴-1,3-二甲基-1H-吡唑-5-羧酸 | 5775-88-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-溴-1,3-二甲基-1H-吡唑-5-羧酸
• 中文别名: 4-溴-2,5-二1-甲基吡唑-3-羧酸；4-溴-2,5-二甲基-3-吡唑羧酸；4-溴-2,5-二甲基-吡唑-3-羧酸
• 英文名称: 4-bromo-1,3-dimethyl-1H-pyrazole-5-carboxylic acid
• 英文别名: 4-bromo-2,5-dimethyl-2H-pyrazole-3-carboxylic acid；4-Brom-2,5-dimethyl-2H-pyrazol-3-carbonsaeure；4-bromo-1,3-dimethylpyrazole-5-carboxylic acid；4-bromo-2,5-dimethylpyrazole-3-carboxylic acid
• CAS: 5775-88-2
• 化学式: C₆H₇BrN₂O₂
• mdl: MFCD02090873
• 分子量: 219.038
• InChiKey: ZUEAEVZRYGUFPS-UHFFFAOYSA-N

物化性质

• 熔点：
  230-232
• 沸点：
  344.0±42.0 °C(Predicted)
• 密度：
  1.80±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 安全说明：
  S26,S37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	4-Bromo-1 3-dimethyl-1h-pyrazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	5775-88-2

Section 1 - Chemical Product MSDS Name:4-Bromo-1 3-dimethyl-1h-pyrazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5775-88-2	4-Bromo-1,3-dimethyl-1H-pyrazole-5-car	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5775-88-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 230 - 232 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7BrN2O2
Molecular Weight: 219.04

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5775-88-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5775-88-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5775-88-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5775-88-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-1,3-二甲基-1H-吡唑-5-羧酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以57%的产率得到(4-bromo-1,3-dimethyl-1H-pyrazol-5-yl)methanol
  参考文献：
  名称：

  一系列具有高亲和力和选择性的MCL-1抑制剂的结构指导设计

  摘要：

  髓样细胞白血病1（MCL-1）是一种BCL-2家族蛋白，与多种肿瘤类型的进展和生存有关。在本文中，我们报告了一系列MCL-1抑制剂，这些抑制剂源于高通量筛选（HTS）命中并通过结构指导设计的迭代循环进行。该系列的先进化合物对MCL-1表现出亚纳摩尔亲和力，并且与其他BCL-2家族蛋白以及多种激酶和GPCR相比具有出色的选择性。在依赖MCL-1的人类肿瘤细胞系中，化合物30b的施用迅速诱导胱天蛋白酶激活，并伴有细胞活力的丧失。因此，本文所述的小分子包含用于研究MCL-1生物学的有效工具。

  DOI：

  10.1021/jm501258m
• 作为产物：
  描述：

  3-甲基吡唑-5-甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 氯仿 、 丙酮 为溶剂， 反应 26.0h， 生成 4-溴-1,3-二甲基-1H-吡唑-5-羧酸
  参考文献：
  名称：

  Synthesis and anti-TMV activity of novel N-(3-alkyl-1H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides

  摘要：

  In order to investigate the biological activity of novel bis-pyrazole compounds, a series of N-(3-alkyl-5-(N-methylcarbamyl)-1 H-pyrazol-4-yl)-3-alkyl-4-substituted-1H-pyrazole-5-carboxamides were designed and synthesized with ethyl 3-alkyl-1H-pyrazole-5-carboxylate 1 as starting materials. N-Methyl-3-alkyl-4-amino-1H-pyrazole-5-carboxamides 6 were obtained from 1 via 5 steps. 3-Alkyl-4-substitued-1H-pyrazole-5-carboxyl chlorides 4a, 4b, 11a, 11b, 11c or 12 were also obtained from 1 via several steps. Target compounds 7a-7g were obtained after the reaction of 6 with the above 1H-pyrazole-5-carboxyl chlorides. Preliminary bioassay showed some compounds possessing good inactivation effect against TMV (tobacco mosaic virus). Compound 7a showed higher activity superior to ningnanmycin at a concentration of 5.0 x 10(-4) g/mL and equal activity it 1.0 x 10(-4) g/mL; 7b and 7c showed equal activity to virazole both at concentrations of 5.0 x 10(-4) g/mL and 1.0 x 10(-4) g/ML. (C) 2012 De Kai Yuan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2012.04.010

文献信息

• [EN] BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES<br/>[FR] DÉRIVÉS DE BENZPYRAZOLE EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147188A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体来说，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• Fused Bicyclic Kinase Inhibitors
  申请人：Mulvihill Mark J.

  公开号：US20110281888A1

  公开（公告）日：2011-11-17

  Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

  公式I的化合物如下所示并在此定义： 其药用可接受盐、合成、中间体、配方以及使用其进行疾病治疗的方法，包括治疗癌症，如至少部分由RON、MET或ALK驱动的肿瘤。本摘要不限制该发明。
• [EN] SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI
  申请人：ABIDE THERAPEUTICS INC

  公开号：WO2019046318A1

  公开（公告）日：2019-03-07

  Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供的化合物和组合物可用作MAGL的调节剂。此外，这些化合物和组合物可用于治疗疼痛。
• IMIDAZOPYRIMIDINE DERIVATIVES
  申请人：Alvarez Sánchez Rubén

  公开号：US20110237564A1

  公开（公告）日：2011-09-29

  The invention is concerned with novel imidazopyrimidine derivatives of formula (I) wherein R 1 , R 2 and R 8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.

  本发明涉及式(I)的新型咪唑并嘧啶衍生物，其中R1、R2和R8如说明书和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物抑制PDE10A，可用作药物。
• [EN] N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS<br/>[FR] DÉRIVÉS DE N-(IMIDAZOPYRIMIDIN-7-YL)-HÉTÉROARYLAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE PDE10A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011117264A1

  公开（公告）日：2011-09-29

  The invention is concerned with novel imidazopyrimidine derivatives of formula (I) wherein R1, R2 and R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDEIOA and used as medicaments.

  本发明涉及通式(I)的新型咪唑并嘧啶衍生物，其中R1、R2和R8如说明书和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物抑制PDEIOA并可用作药物。

表征谱图